Jason Kelly Sells 963 Shares of Inspire Medical Systems (NYSE:INSP) Stock

Inspire Medical Systems, Inc. (NYSE:INSPGet Free Report) insider Jason Kelly sold 963 shares of the firm’s stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $59.55, for a total value of $57,346.65. Following the transaction, the insider owned 18,985 shares of the company’s stock, valued at $1,130,556.75. This trade represents a 4.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Inspire Medical Systems Stock Performance

Shares of INSP stock opened at $57.97 on Thursday. Inspire Medical Systems, Inc. has a fifty-two week low of $38.91 and a fifty-two week high of $147.03. The stock has a market capitalization of $1.68 billion, a P/E ratio of 12.55, a price-to-earnings-growth ratio of 4.49 and a beta of 0.70. The company has a 50 day moving average price of $48.74 and a 200 day moving average price of $53.59.

Inspire Medical Systems (NYSE:INSPGet Free Report) last posted its quarterly earnings results on Monday, August 3rd. The company reported $0.14 EPS for the quarter, topping the consensus estimate of ($0.24) by $0.38. Inspire Medical Systems had a net margin of 15.03% and a return on equity of 8.64%. The business had revenue of $200.58 million during the quarter, compared to the consensus estimate of $194.72 million. During the same quarter in the previous year, the firm posted $0.45 earnings per share. The company’s quarterly revenue was down 7.6% compared to the same quarter last year. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. On average, research analysts forecast that Inspire Medical Systems, Inc. will post 1.24 EPS for the current fiscal year.

Institutional Investors Weigh In On Inspire Medical Systems

Several hedge funds have recently modified their holdings of the company. BlackRock Inc. purchased a new stake in Inspire Medical Systems in the 2nd quarter worth approximately $211,341,000. Wellington Management Group LLP purchased a new stake in Inspire Medical Systems during the fourth quarter valued at about $203,929,000. Wasatch Advisors LP increased its position in Inspire Medical Systems by 7.2% during the 2nd quarter. Wasatch Advisors LP now owns 1,634,395 shares of the company’s stock worth $212,095,000 after purchasing an additional 110,288 shares in the last quarter. Morgan Stanley increased its position in shares of Inspire Medical Systems by 179.5% in the fourth quarter. Morgan Stanley now owns 1,259,762 shares of the company’s stock worth $116,188,000 after acquiring an additional 809,121 shares in the last quarter. Finally, Deerfield Management Company L.P. increased its holdings in Inspire Medical Systems by 648.4% in the 3rd quarter. Deerfield Management Company L.P. now owns 1,047,694 shares of the company’s stock valued at $77,739,000 after purchasing an additional 907,694 shares in the last quarter. 94.91% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on INSP shares. Stifel Nicolaus set a $75.00 price objective on Inspire Medical Systems in a research report on Tuesday, August 4th. Evercore set a $54.00 price target on shares of Inspire Medical Systems in a research note on Tuesday, August 4th. Oppenheimer upgraded Inspire Medical Systems from a “market perform” rating to an “outperform” rating and set a $85.00 target price on the stock in a research note on Tuesday, August 4th. Zacks Research raised shares of Inspire Medical Systems from a “strong sell” rating to a “hold” rating in a report on Monday, July 6th. Finally, Freedom Capital upgraded Inspire Medical Systems to a “strong-buy” rating in a research note on Tuesday, June 30th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, thirteen have issued a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat.com, Inspire Medical Systems currently has a consensus rating of “Hold” and a consensus target price of $68.00.

Read Our Latest Analysis on INSP

About Inspire Medical Systems

(Get Free Report)

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.

See Also

Receive News & Ratings for Inspire Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inspire Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.